{"id":1647,"date":"2024-10-29T11:22:18","date_gmt":"2024-10-29T09:22:18","guid":{"rendered":"https:\/\/www.parthenogenesis.gr\/?post_type=pg-product&p=1647"},"modified":"2025-09-17T13:19:37","modified_gmt":"2025-09-17T10:19:37","slug":"redostim","status":"publish","type":"pg-product","link":"https:\/\/www.parthenogenesis.gr\/en\/pg-product\/redostim\/","title":{"rendered":"Redostim\u00ae"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Redostim\u00ae is the natural solution for an effective luteal phase support and for the support of the1st trimester of pregnancy. The formula of Redostim\u00ae stimulates the endogenous release of hydrogen sulphide (H\u2082S) by the cells of the uterus.<\/p>

Moreover, the natural formula of Redostim helps efficiently to reduce period pain regardless of the woman\u2019s age.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t
The mechanism of action of Redostim <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/path><\/svg><\/span>\n\t\t\t<\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
  • Redostim\u00ae is used concomitantly with estrogens and progesterone to regulate microvascular permeability of the endometrium (better implantation).<\/li>
  • Co-administration of Redostim\u00ae with progesterone reduces inflammation factors in the endometrium to maintain uterine calm throughout pregnancy.<\/li>
  • Redostim\u00ae reduces inflammation factors during menstruation (period) resulting in a noticeable reduction of pain during the first days of menstruation.<\/li><\/ul>

    \u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t

    \n\t\t\t\t\n\t\t\t\t\t
    Dosage <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/path><\/svg><\/span>\n\t\t\t<\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t

    Luteal phase support<\/h1>

    Loading dose<\/h4>
    • 3 tablets once daily (take in the morning on an empty stomach)<\/strong><\/li>
    • Duration of treatment until pregnancy test<\/li><\/ul>

      Maintenance dose<\/h4>
      • 2 Tablets once\/Day (Taken in the morning on an empty stomach)<\/strong><\/li>
      • The repeat dose begins if and when there is a positive pregnancy test and lasts until the 12th week of pregnancy.<\/li><\/ul>

        Treating Period Pain<\/h3>

        The dosage regimen begins at the end of the woman’s period.<\/p>

        1. For the first month that the woman begins taking the product, she should
          • Take 2 tablets once a day\/ on a daily base (in the morning on an empty stomach).<\/li>
          • REDOSTIM should be taken for 30 consecutive days.<\/li><\/ul><\/li>
          • From the second month of treatment
            • The dosage regimen continues from the 15th day after the end of the last menstrual period (period).<\/li>
            • The dosage is 2 tablets once a day\/ on a daily base until the 2nd day of the next period.<\/li><\/ul><\/li>
            • For each subsequent month and thereafter, follow step 2.<\/li><\/ol>

              Redostim can be taken for long periods of time.<\/p>

              The product is available in all Greek and online pharmacies.<\/p>

              The Ministry of Health and the National Organization for Medicines recommend:<\/p>

              • Do not exceed the recommended daily dose.<\/li>
              • Keep out of reach of small children.<\/li>
              • Dietary supplements should not be used as a substitute for a varied and balanced diet and a healthy lifestyle. This product is not intended to prevent, treat, or cure human disease.<\/li>
              • Consult your doctor if you are pregnant, breastfeeding, taking medication, or have health problems.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t
                \n\t\t\t\t\n\t\t\t\t\t
                Qualitative & quantitative composition <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/path><\/svg><\/span>\n\t\t\t<\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
                \n\t\t\t\t
                \n\t\t\t\t
                \n\t\t\t\t\t\t\t\t\t

                QUALITATIVE & QUANTITATIVE COMPOSITION: Redostim \u00ae 20.8 mg, film-coated tablet<\/span><\/p>

                Each film-coated tablet contains:<\/p>
                composition
                (composition with nutritional\/physiological action) <\/th>                		Per daily dose (2 tablets)<\/th>% DHW*<\/th><\/tr>
                L- cystine<\/td>250mg<\/td>–<\/td><\/tr>
                L- taurine<\/td>250mg<\/td>–<\/td><\/tr>
                5-phosphate pyridoxal<\/td>10mg<\/td>714<\/td><\/tr><\/tbody><\/table>

                *NDR: Nutritional reference value according to regulation (EU) 1169\/2011<\/p>

                REDOSTIM\u00ae is gluten free & lactose.<\/p>

                Product notified by National Organization for Medicines (EOF): 47390\/21-05-2021<\/p>

                The notification to EOF is not a marketing authorization by EOF.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t

                \n\t\t\t\t\n\t\t\t\t\t
                References <\/div><\/span>\n\t\t\t\t\t\t\t\n\t\t\t<\/path><\/svg><\/span>\n\t\t\t<\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t
                \n\t\t\t\t
                \n\t\t\t\t
                \n\t\t\t\t\t\t\t\t\t
                1. Dattilo M et al (2022). Nutrition and Metabolic Insights; Volume 15: 1\u201313<\/li>
                2. Qi Q-R et al (2020). Endocrinology 2020; 161(11); bqaa176<\/li>
                3. Papapostolou et al. The J. of Maternal-Fetal and Neonatal Med 2013<\/li>
                4. Chen D-B et al (2017). Biology of Reproduction, 2017; 97(3), 478\u2013489<\/li>
                5. Malamitsi-Puchner et al. Fertil Steril, 2004 ; 81:13227.<\/li>
                6. Zhang et al. J Clin Endocrinol Metab, 2017 ; 102: 2382\u20132393,<\/li>
                7. Sun et al. American Society for Investi. Pathology, 2018 ; 188: 63-71<\/li>
                8. Chung CHS et al (2017). Reprod Biomed Online 2017; 34(3): 240-247<\/li>
                9. Olson DM et al. Pract Res Clin Obstet Gynaecol 2003; Volume 17, Issue 5, Pages 717-730<\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":1574,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"class_list":["post-1647","pg-product","type-pg-product","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.parthenogenesis.gr\/en\/wp-json\/wp\/v2\/pg-product\/1647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.parthenogenesis.gr\/en\/wp-json\/wp\/v2\/pg-product"}],"about":[{"href":"https:\/\/www.parthenogenesis.gr\/en\/wp-json\/wp\/v2\/types\/pg-product"}],"version-history":[{"count":4,"href":"https:\/\/www.parthenogenesis.gr\/en\/wp-json\/wp\/v2\/pg-product\/1647\/revisions"}],"predecessor-version":[{"id":1759,"href":"https:\/\/www.parthenogenesis.gr\/en\/wp-json\/wp\/v2\/pg-product\/1647\/revisions\/1759"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.parthenogenesis.gr\/en\/wp-json\/wp\/v2\/media\/1574"}],"wp:attachment":[{"href":"https:\/\/www.parthenogenesis.gr\/en\/wp-json\/wp\/v2\/media?parent=1647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}